Karuna Therapeutics, Inc. - KRTX EV/Sales Multiple

karunatx.com (KRTX) - corporate logo

Karuna Therapeutics (KRTX) has solidified its leadership status in schizophrenia therapy thanks to its breakthrough drug KarXT. The company's price-to-sales multiple clearly demonstrates the market valuation, where the current level equals . Experienced management ensured a successful merger with a pharma behemoth, although risks regarding side effects and fierce competition for safe molecules persist within the psychotropic drug niche.

Karuna - KRTX Company Value to Revenue (period 07/04/2022 - 11/20/2026)

Karuna Therapeutics Inc - analytical breakdowns and key metrics (KRTX)

- current quotes and average value forecast:
- cash and cash flow indicators:
Fundamental valuation:Karuna Therapeutics, Inc. KRTX
Finished products of Karuna Therapeutics, Inc.

Reliable psychopharmaceutical distribution and production diversification at Karuna Therapeutics (KRTX) create a foundation for high margins, which investors analyze via the company's EV/Sales ratio. This metric compares the total enterprise value with revenue regardless of debt load, allowing for an assessment of the real value of assets amid compressing multiples and the tight monetary policy of the US Federal Reserve.